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BACKGROUND: Early detection of lung cancer saves lives, as demonstrated by the two largest published low-dose CT 
screening trials. Optimal implementation depends on our ability to identify those most at risk.  
METHODS: Version 2 of the Liverpool Lung Project risk score (LLPv2) was developed from case-control data in Liverpool and 
further adapted when applied for selection of subjects for the UK Lung Screening Trial (UKLS). The objective was to produce 
version 3 (LLPv3) of the model, by calibration to national figures for 2017. We validated both LLPv2 and LLPv3 using 
questionnaire data from 75,958 individuals, followed up for lung cancer over 5 years. We validated both discrimination, using 
ROC analysis, and absolute incidence, by comparing deciles of predicted incidence with observed incidence. We calculated 
proportionate difference as the percentage excess or deficit of observed cancers compared to those predicted. We also 
carried out Hosmer-Lemeshow tests. 
RESULTS: There were 599 lung cancers diagnosed over 5 years. The discrimination of both LLPv2 and LLPv3 were significant 
with an area under the ROC curve (AUC) of 0.81 (95% CI 0.79 - 0.82). However, LLPv2 overestimated absolute risk in the 
population. The proportionate difference was -58.3% (95% CI -61.6% - -54.8%), i.e. the actual number of cancers was only 42% 
of the number predicted.  
In LLPv3, calibrated to national 2017 figures, the proportionate difference was -22.0% (95% CI -28.1% - -15.5%).  
CONCLUSIONS: Whilst LLPv2 and LLPv3 have the same discriminatory power, LLPv3 improves the absolute lung cancer risk 
prediction and should be considered for use in further UK implementation studies.  
 
Key Messages 
What is the key question? 
The Liverpool Lung Project risk model (LLPv2) has been developed to identify those at high risk of lung cancer for intervention 
(e.g. by low dose CT in the UKLS trial), here we assess the discriminatory and predictive power of the risk model and propose 
an updated version (LLPv3) more suitable for a contemporary country-wide population. 
What is the bottom line? 
The LLPv2 risk model was validated with a significant discriminatory power, but overestimates risk compared to the improved 
LLPv3. 
Why read on? 
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We demonstrate an improved risk prediction model for lung cancer, by relatively simple a priori calibration to updated cancer 
incidence data. 
Number of words 3,940 
 
INTRODUCTION 
Evidence from randomised trials estimates a significant 20% reduction in lung cancer mortality with invitation to low dose CT 
screening 1 2. In the US, lung cancer screening has been recommended by the United States Preventive Services Task Force 
(USPSTF) and in other countries there are a growing number of implementation studies aimed at addressing outstanding 
pragmatic issues of wider roll out for national programmes. An issue of fundamental importance is identification of a 
population at sufficient risk of disease to optimise detection in those who would benefit from screening for lung cancer, 
minimise unnecessary investigations for those at low risk and provide a cost-effective programme. While there is ample 
evidence on the discriminatory power of various risk prediction tools, there is a need to validate these tools on prospectively 
collected data to estimate their predictive power, as recommended by Toll et al 3 and as performed by Ten Haaf et al 4.  
The Liverpool Lung Project risk model was developed on a case-control study in Liverpool and provides a percentage risk score 
for an individual over the next 5 years, based on questionnaire data 5. It has been validated in three international data sets and 
had an AUC of 0.82 in the UK Cohort 6. It was later amended (LLPv2) due to observations in the UK Lung Screening (UKLS) Trial 
7 8 in which it was used to select subjects for low-dose CT screening. In this paper we report on further amendments to the 
model (LLPv3) calibrated to the whole of England and to more recently available lung cancer incidence data, with prospective 
validation in a large cohort covering two regions of England. 
 
METHODS  
Development and calibration 
The LLP risk model was derived from data relating to 579 individuals with lung cancer and 1,157 controls, recruited between 
1998 and 2005 in an area of North West England. Variables included in the model were age, sex, cigarette smoking history, 
prior diagnosis of pneumonia, occupational exposure to asbestos, prior diagnosis of malignant tumour, and family history of 
lung cancer. The model development process and internal validation have been published elsewhere 5. 
A second version of the model (LLPv2) was subsequently developed, following observations in the UKLS that resulted in 
changes to two variables: previous diagnoses of other lung diseases were considered alongside pneumonia, and cigar and pipe 
smoking were included alongside cigarettes 8. The change was prompted by the observation in UKLS that those included on 
the basis of duration of use of other smoking materials had at least the prevalence of lung cancer as those included with the 
same duration of cigarette smoking 7. The numerical parameters of the model remained unchanged. Model formulation is 
given in Supplementary Material 1. The LLP risk models only use smoking duration, as in common with others 9 10 11, we found 
this to be the strongest predictor of the various smoking metrics, and other aspects such as amount smoked, were not 
significant when adjusting for duration 4. 
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The age-standardised incidence ratio for lung cancer in Liverpool compared to England as a whole for the years 2012-16 was 
1.86 12. The age-standardised rates of newly diagnosed cases of lung cancer for England were 101.4 per 100,000 of population 
for males in 2006 and 57.9 for females; the corresponding rates in 2017 (the most recent year for which these data were 
available) were 86.8 and 67.0 respectively 13. In order to produce an updated version of the model (LLPv3) for current use in 
the UK, the age-related risk factors in the model were each adjusted to approximate the effect of reducing the calculated risk 
score by a factor of 1.86 x 101.4 / 86.8 for males and 1.86 x 57.9 / 67.0 for females, in the absence of any other risk factors 
(see Supplementary Material 1). 
Validation 
Participants for the UKLS were recruited from people aged 50-75 (at the time of initial approach) living in the areas covered by 
six Primary Care Trusts in two regions of the UK (North West England and East of England), by means of a questionnaire sent 
to just under a quarter of a million people. Recruitment methods and participant rates for UKLS have been reported elsewhere 
8. Ethical approval for the study was given by Liverpool Central Research Ethics Committee in December 2010 (reference 
number 10/H1005/74). 
Of the 75,958 people who expressed an interest in participating in the study (by completing and returning the questionnaire 
between September 2011 and March 2013), 8,729 were assessed to have a high-risk score (estimated 5% risk or higher over 
five years) for lung cancer. After exclusions, 4,061 gave informed consent for low dose CT randomisation and biosample 
provision. Of these, 2,028 were randomised to the CT screening arm (intervention) and 2,027 to the non-screening arm 
(control); the remaining 6 were not randomised. 
The questionnaire sent out as part of the initial approach for recruitment to the trial used a standardised format (see 
Supplementary Material 2) and covered personal history of non-malignant lung diseases, previous malignancy, exposure to 
asbestos, family history of lung and other cancers, and smoking history. For all those who had ever smoked regularly, 
questions covered the type of smoking material, quantity, and the age of starting and (if applicable) stopping smoking. For 
validation of the amended model (LLPv3), we used prospective data for the 75,958 people who returned the initial 
questionnaire. Coding and interpretation details are given in Supplementary Material 3. 
Cancer and death registration data between 2011 and 2018 were obtained from Public Health England (PHE) and linked 
through NHS number by a third party to the research cohort (PHE Office of Data Release study 1819_074). This provided the 
minimum of five years of follow up required for testing the LLP model. Only diagnoses within the first five years were taken 
into account.  
A risk score representing cancer risk over five years was calculated for each individual from the questionnaire data using both 
LLPv2 and LLPv3. The input variables were derived according to the algorithms shown in the online supplementary material.  
A receiver operating characteristic (ROC) curve was plotted to assess the ability of the model to successfully distinguish 
between those persons who went on to develop lung cancer and those who did not. The ROC curve is a plot of the true 
positive rate (or sensitivity) against the false positive rate (1 – specificity) for different risk scores. The area under the curve 
(AUC) was calculated, along with the corresponding 95% confidence interval. 
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Individuals allocated to the intervention arm of the UKLS trial, nested within the validation cohort, may have potentially 
received additional diagnostic procedures in the form of low-dose CT scans, compared to the rest of the study population. In 
order to investigate the possible impact of this, sensitivity analysis was carried out, excluding this subgroup. 
In order to assess the calibration of the predictive model, we ranked the LLPv3 risk scores, assigned decile groups, and carried 
out a linear regression of the log-odds (𝑓(𝑥) = log!
"
#$"
) of the rate of observed cancers in each group against the log-odds of 
the mean of the risk scores in the group. The proportionate difference (the number of cancers observed in excess or deficit of 
those that would have been expected based on the risk scores, divided by that expected number) was also calculated. In 
addition, we carried out Hosmer-Lemeshow tests, with the population classified by predicted risk deciles 14. However, 
interpretation of these has to be qualified by the test’s sensitivity to categorisation, sample size and ties 15 16 17. 
Statistical analyses were performed using STATA, version 15.1 (StataCorp, College Station, Texas). 
 
RESULTS 
Table 1 shows the basic demographic and risk profile of the study population, and of the subgroup developing lung cancer. 
Overall, almost half the population were male, 65% were aged 60 years or over, 18% were in the most deprived IMD quintile, 
and more than half the population had smoked at some time in their lives. As expected, the lung cancer cases were older, had 
higher rates of smoking and were more deprived than the overall population. 
Lung cancers were diagnosed in a total of 599 people over the period of follow-up (five years from the questionnaire 
completion date), i.e. 0.8% of the study population. Table 2 shows the number of cancers that were potentially detectable, i.e. 
occurring in subjects who qualify for surveillance and those occurring in subjects who do not qualify using the amended LLP 
model (assuming 100% sensitivity of CT screening) for selected referral thresholds. The table also shows the corresponding 
sensitivity and specificity of exceeding the threshold. Results are given for males and females separately, and overall. Under 
LLPv2, a threshold of 3.7% would have yielded 10,864 subjects qualifying. The equivalent threshold under LLPv3 would be 
2.0%. The numbers needed to screen (with the risk model) per cancer potentially detectable, fall from 62 with a 0.5% LLPv3 
threshold to 21 with a 4.5% threshold. The positive likelihood ratios increased from 2.0 at the LLPv3 0.5% threshold to 6.3 at 
the 4.5% threshold. The corresponding ranges for males only were 1.9-5.4 and for females 2.3- 7.8. 
The ROC curve for LLPv3 is given in Figure 1. The curves for LLPv2 and LLPv3 are almost identical, as would be expected, since 
the coefficients pertaining to the risk factors are the same, and the ranking of most individuals is unchanged from version 2 to 
version 3. As a result, the discrimination is very similar. The AUC in each case was 0.81 (95% CI 0.79 - 0.82). After excluding 
individuals allocated to the UKLS trial intervention arm, the AUC and 95% confidence interval were also unchanged. 
The numbers of cancers detected by LLP decile groups and the expected numbers of cancers in each group are given in Table 
3, for both LLPv2 and LLPv3. Corresponding figures separately for males and females are given in Supplementary Material 4. 
The increasing actual risk with predicted risk can be seen from the increasing percentage of cancers in successive risk deciles. 
The 10% of subjects in the second decile of predicted risk by LLPv3 contribute 2% (12/599) of the cancers whereas the 10% in 
the 6th decile contribute 4% (24/599) and the 10% in the highest decile contribute 45% (269/599).  
Figure 2 shows the log odds of the observed rate of cancers (with 95% confidence intervals) plotted against the log odds of the 
mean risk score for both LLPv2 and LLPv3.  
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For LLPv2, the slope of the calibration line was 0.88 (95% CI 0.74 – 1.02), and the intercept at the origin (corresponding to a 
risk score of 50%) was -1.31 (95% CI -1.96 – -0.66). The orange line represents perfect agreement between observed and 
expected cancers, indicating that the LLPv2 model overestimated the risk. The proportionate difference was (599-1,436)/1,436 
or -58.3% (95% CI -61.6% - -54.8%). 
For LLPv3, the slope was largely unchanged at 0.90 (95% CI 0.75 – 1.05), the intercept at the origin was -0.66 (95% CI -1.46 – 
0.15), and the proximity to the orange line indicates reduced discrepancy between observed and expected cancers. There was 
still a tendency to overestimate the number of cancers, especially at the highest risk levels, but the proportionate difference 
was considerably lower, at -22.0%. 
Figure 3 shows the corresponding graphs for LLPv3 for males and females separately. The slope for males was 0.89 (95% CI 
0.79 - 0.99) and the intercept was -0.74 (95% CI -1.28 - -0.21). For females, there was stronger agreement between predicted 
and observed numbers, with a slope of 0.93 (95% CI 0.72 – 1.14) and an intercept of 0.47 (95% CI -1.6 - +0.65). 
The corresponding Hosmer-Lemeshow tests yielded a chi-squared of 530.06 (p<0.001) for LLPv2 overall, with 437.78 (p<0.001) 
for males and 110.18 (p<0.001) for females. For LLPv3, a considerably improved fit was shown, with the Hosmer-Lemeshow 
statistics reduced by a factor of 10, with chi-squared statistics of 50.87 (p<0.001) overall, 43.82 (p<0.001) for males and 15.19 
(p=0.06) for females. In the figures for LLPv3, overall and males only, 65% and 73% respectively of the chi-squared figures 
were contributed by the highest decile. This can also be seen in Table 3 and Supplementary Material 4. 
 
DISCUSSION 
We present an updated version of the LLP model (LLPv3) designed to assess risk of lung cancer in the next five years for the 
contemporaneous English population. Its primary intended use is to identify people who might benefit from lung cancer 
screening. We recalibrated the LLPv2 model used in the UKLS trial of lung cancer screening taking account of changes to the 
age and sex specific lung cancer risk profile of England and the difference in risk between the Liverpool area and England as a 
whole. We prospectively validated the LLP model by using baseline risk factors and follow-up of lung cancer diagnoses in a 
large cohort (>75,000) of individuals expressing interest in the UKLS study. This demonstrated excellent discrimination based 
on an AUC measure of 0.81 (95%CI 0.79 - 0.82) for both LLPv2 and the updated LLPv3. The newer model also provided a very 
good estimation of future risk through comparison of observed and expected lung cancer outcomes.  
However, without the calibration to the current England population in terms of age and sex specific lung cancer risk, there 
would have been considerable overestimation of risk. This is consistent with the findings of Katki et al 18, who concluded that 
previous versions of the LLP model overestimated future incidence.  
Risk-based lung cancer screening strategies prevent significantly more lung cancer deaths than the current the US Preventive 
Services Task Force (USPSTF) recommendations on lung cancer screening 19, which is currently the only internationally 
approved government stratification system and is also supported by the USA medical care agency (Medicare) 20-23. Two lung 
cancer risk prediction models have been previously used in lung cancer CT screening clinical trials, the PanCan risk model 
(precursor to the PLCOM2012 model), in the PanCan cohort CT trial 24 and the LLPv2 in the UKLS trial 8. The PanCan model did 
show good overall discrimination, however, it underestimated the observed risk of lung cancer by 30%. The authors tested 
both the PanCan and the PLCOm2012 in the PLCO trial “ever smokers” and found small differences in the overall prediction, 
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discrimination and calibration 24. A number of other lung cancer risk models have been developed and although some have 
been tested in previously recruited NLST subjects and a subgroup of the PLCO population, none have been used as the basis 
for eligibility in the clinical trial environment 4. 
The UKLS was a pilot CT screening trial and a pragmatic decision was made to select individuals with a 5% predicted risk of 
developing lung cancer over a 5-year period, in order to ensure the trial had a large number of lung cancers. This objective was 
successfully achieved, as 2.2% of subjects with lung cancer were identified in the baseline screen, which was significantly 
higher than either the NLST 1 or NELSON 2 trials. It was acknowledged that the risk cut off might be lower in a large national 
screening programme 25.  
The discriminatory power of the LLPv2 was significant with an AUC of 0.81, however the model was found to overestimate the 
absolute risk approximately two fold. The LLP risk model was based on a very high-risk population recruited between 1997-
2005 in the NW of England and the incidence rates for lung cancer included in the model were based on 2007 data. On 
calibrating the age and gender specific intercepts to the current English data 12 13, a recalibrated LLP risk model is now 
provided here (LLPv3 risk model). As the calibration was independent of the data available from the UKLS study, we were able 
to use that to validate the model. The recalibrated LLPv3 model demonstrated a significantly improved absolute prediction 
with the expected rates of cancer in the population, as demonstrated by the correlation between the risk score and the 
observed cancer rates. 
While the prediction as measured by the Hosmer-Lemeshow test is not perfect, we note the reservations about this test 
specified above. We also note that the LLPv3 clearly predicts better for women than for men, and that the only substantial 
departure of observed from predicted numbers is in one extreme category, the highest decile of risk, and in males only. 
We acknowledge there are a number of limitations, however, many are shared by similar risk model studies. Firstly, the study 
population, although large at 75,958, represents a self-selecting group from 247,354 individuals (30.7%) approached for the 
UKLS trial. Potentially, there is over-representation of lower risk, better educated, “worried well” individuals (often associated 
with higher socio-economic groups) 26. On examining the UKLS IMD quintiles, the two least deprived (51.2%) outnumber the 
two most deprived (31.2%); however, it should be acknowledged that the LLP risk score is predictive across all IMD quintiles 
and a similar IMD profile would be expected on the introduction of national screening. There is a recognition that more should 
be done to target the “hard to reach” individuals in lower socio-economic groups, who have higher rates of lung cancer (as 
confirmed here: most deprived quintile 15.4 per 1000 in 5 years, least deprived 5.1).  
Secondly, the UKLS study population represents a limited geographical sub-population of the UK (both in the North West and 
the East of England), and one of the areas overlaps considerably with the area supplying the original estimation data set. 
However, no individual appears in both estimation and validation sets, and the validation set appears to be broadly 
representative as demonstrated by the fit achieved for risk calibrated to data for England as a whole. This highlights that 
basing a risk score on a defined region (i.e. Liverpool) one may overestimate lung cancer risk if that region has a higher 
incidence than the rest of the country. When extrapolating risk models from smaller studies in defined regions we therefore 
recommend that this is taken into account. 
In terms of discrimination, previous retrospective validation exercises on LLPv2 have shown a range of discriminatory 
capacities, with AUCs ranging from 0.67 to 0.82 6. However, the lower figure pertains to a cohort undergoing surgery, which 
would not necessarily be representative of lung cancer cases as a whole. 
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Primary care data is usually not sufficient to supply the risk factors in this model, or in most other lung cancer risk models 18 4. 
The paradigm for selection of individuals for additional lung cancer surveillance or prevention is to use a crude risk criterion 
such as ever smoking to select candidates from primary care, then carry out a formal risk assessment as part of a lung health 
check on those candidates using a tool such as one of the LLP or PLCO models. This has been used in the Lung Screen Uptake 
Trial 27, the Yorkshire Lung Screening Trial 28, and the Manchester 29 and Liverpool 30 demonstration projects. 
We note here that the LLPv2 and LLPv3 are essentially aimed at risk of lung cancer in the next five years. They are not 
diagnostic tests for lung cancer. As such the positive likelihood ratios are low in comparison with some diagnostic tests. The 
clinical utility of our preferred risk tool, LLPv3 will depend on what intervention might be triggered by a given risk level. The 
most obvious intervention would be surveillance with low dose CT, but this need not be the only response to lung cancer risk. 
In this paper, therefore, we have concentrated on accuracy of the prediction, and have not introduced further dimensions 
such as clinical or public preference. Detailed clinical implications of different risk thresholds using LLPv3 will be the subject of 
a future paper. This will likely include Decision Curve Analysis and possibly other tools such as Mean Risk Stratification and 
Incremental Net Benefit  31 32 33. 
The LLPv2 and PLCOm2012 have been utilised and initial data published in three UK lung cancer early detection / CT screening 
implementation projects, the Liverpool Healthy Lung Programme (LLPv2) 30, the Lung Screen Uptake Trial 27, and the West 
London Lung Cancer Screening pilot (WLLCS) 34. All three of these projects successfully selecting high risk patients and 
identified early stage lung cancers. The Yorkshire Lung Screening trial 28 has also utilised the LLPv2 and PLCOm2012 risk models, 
however the results have not as yet been published. 
The WLLCS pilot has published its base line data on both the LLPv2 and PLCOm2012 risk models. The authors reported that 1,159 
participants were eligible for a CT scan, of which 451/1,159 (38.9 %) had a LLPv2 ≥2.0 % ; only 71/1,159 (6.1 %) had a 
PLCO M2012 ≥1.5 %, lung cancer was detected in 29/1,145 (2.5 %) participants scanned 5/29 participants with lung cancer did 
not meet a PLCO M2012 threshold of ≥1.51 %; however, all had a LLPv2 ≥2.0 %. 
The Manchester Health Lung Check (MLHC) selected patients for their study with the PLCOm2012 risk model. They have recently 
analysed the performance of both the LLPv2 and PLCOm2012 models in their data set 35, utilising ≥2.5% LLPv2 risk model and 
>1.51 % Risk calculated from the PLCOm2012 model. In the MLHC 1430 dataset, the authors calculated that 93.5% (58 of the 62 
identified) of the lung cancer cases would have been identified by the LLPv2 ≥2.5% risk; with a further 272 participants who 
would have been eligible with LLPv2 but ineligible with PLCOm2012, however, the outcome of these individuals was unknown.  
An international comprehensive analysis of seven lung cancer risk models, (including LLPv1) has been undertaken utilising data 
from the PLCO and NLST data sets 4. However a number of the LLPv1 parameters were not available; asbestos exposure, nor 
history of pneumonia, nor the age of diagnosis of the first degree relatives’ family history of lung cancer in the PLCO and NLST 
datasets. Ten Haaf and co-authors reported that all the seven risk models outperformed the NLST trial eligibility criteria over a 
wide range of risk thresholds in decision curve analysis, with a higher sensitivity for all models and a slightly higher specificity 
for a number of the models. The PLCOm2012 outperformed all of the models in their analysis and both the LLPv1 and the 
authors’ simplified LLP risk model did not perform as well, overestimating the risk. However, the validation exercise used the 
LLP v1 model and three of the risk parameters were not available in their test sets.  
 
Given that a likely application for lung cancer risk models such as LLPv3 is determination of eligibility for low dose CT screening 
for lung cancer, it is worth remarking that there is a trade-off between potential increases in cost-effectiveness with higher 
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risk thresholds and likely comorbidities, which may either impair eligibility for potentially curative surgery in those detected 
with lung cancer, or otherwise shorten expected life and thus diminish the potential benefits of screening. See Rivera et al, for 
a thorough exegesis of this issue 36. 
This current analysis provides evidence that the LLPv2 and LLPv3 have the same discriminatory power, but the LLPv3 is now 
recommended for future UK lung cancer CT screening programmes, as it better estimates the absolute lung cancer risk. The 
NHS England ‘Targeted Screening for Lung Cancer with Low Radiation Dose Computed Tomography’ protocol 37 has included 
the use of the PLCOm2012 (at a 1.5% risk cut off) and the LLPv2 (at 2.5% risk cut off). It is now recommended that NHS England 
utilise the LLPv3, which is calibrated to sex and age specific incidence for the whole of England in 2017; a LLPv2 cut off of 2.5% 
equates to a risk cut off of 1.33% over 5 years for LLPv3, so it is in line with the PLCOm2012 of >1.5% over 6 years. To ensure a 
substantially enhanced risk group, it might be prudent to use a 2.5% threshold using LLPv3 (see Table 2). 
In conclusion, discrimination of LLPv2 and LLPv3 was excellent. LLPv3, which was calibrated to contemporary, English 
incidence, achieved more accurate prediction of absolute incidence, and would be more effective in selecting a high-risk group 
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Table 1: Baseline factors and lung cancers diagnosed 
 
All participants (%) 
Participants diagnosed 
with lung cancer within  
5 years (%) 
Cumulative incidence 
per 1,000 of lung 
cancer over 5 years 
All participants 75,958  599  7.9 
Sex      
Male 37,525 (49.4) 327 (54.6) 8.7 
Female 38,433 (50.6) 272 (45.4) 7.1 
Age      
50-54 12,123 (16.0) 21 (3.5) 1.7 
55-59 14,359 (18.9) 54 (9.0) 3.8 
60-64 19,007 (25.0) 148 (24.7) 7.8 
65-69 19,602 (25.8) 224 (37.4) 11.4 
70-74 9,993 (13.2) 134 (22.4) 13.4 
75-79 874 (1.2) 18 (3.0) 20.6 
Region      
North West England 32,609 (42.9) 332 (55.4) 10.2 
East of England 43,349 (57.1) 267 (44.6) 6.2 
IMD quintile      
1 (most deprived) 13,893 (18.3) 214 (35.7) 15.4 
2 9,813 (12.9) 92 (15.4) 9.4 
3 13,337 (17.6) 102 (17.0) 7.6 
4 16,707 (22.0) 77 (12.9) 4.6 
5 (least deprived) 22,198 (29.2) 114 (19.0) 5.1 
Unknown 10 (-) - (-) - 
Smoking duration      
Never 35,535 (46.8) 58 (9.7) 1.6 
1-19 years 10,889 (14.3) 29 (4.8) 2.7 
20-39 years 19,284 (25.4) 208 (34.7) 10.8 
40-59 years 10,204 (13.4) 302 (50.4) 29.6 
60 years or more 46 (0.1) 2 (0.3) 43.5 
History of pneumonia or other lung conditions      
No 57,558 (75.8) 351 (58.6) 6.1 
Yes 18,400 (24.2) 248 (41.4) 13.5 
Personal history of cancer      
No 66,855 (88.0) 493 (82.3) 7.4 
Yes 9,103 (12.0) 106 (17.7) 11.6 
Asbestos exposure      
No 64,796 (85.3) 471 (78.6) 7.3 
Yes 11,162 (14.7) 128 (21.4) 11.5 
Family history of lung cancer      
None 63,321 (83.4) 453 (75.6) 7.2 
Early onset (before age 60) 4,532 (6.0) 77 (12.9) 17.0 





















Number needed to 












(a) Males only 
0.5%  18,190   293  34 62 89.6% 51.9% 1.08% 
1%  11,694   256  71 46 78.3% 69.3% 2.15% 
1.5%  8,683   225  102 39 68.8% 77.3% 3.21% 
2%  6,712   194  133 35 59.3% 82.5% 4.25% 
2.5%  5,140   168  159 31 51.4% 86.6% 5.31% 
3%  4,022   143  184 28 43.7% 89.6% 6.32% 
4.5%  2,104   95  232 22 29.1% 94.6% 9.32% 
(b) Females only 
0.5%  14,347   228  44 63 83.8% 63.0% 0.79% 
1%  8,333   197  75 42 72.4% 78.7% 1.59% 
1.5%  5,425   162  110 33 59.6% 86.2% 2.37% 
2%  4,152   135  137 31 49.6% 89.5% 3.15% 
2.5%  2,992   114  158 26 41.9% 92.5% 3.94% 
3%  2,340   99  173 24 36.4% 94.1% 4.73% 
4.5%  1,079   57  215 19 21.0% 97.3% 7.00% 
(c) All subjects 
0.5% 32,537 521 78 62 87.0% 57.5% 0.90% 
1% 20,027 453 146 44 75.6% 75.0% 1.86% 
1.5% 14,108 387 212 36 64.6% 81.8% 2.89% 
2% 10,864 329 270 33 54.9% 86.0% 3.70% 
2.5% 8,132 282 317 29 47.1% 89.6% 4.78% 
3% 6,362 242 357 26 40.4% 91.9% 5.60% 
4.5% 3,183 152 447 21 25.4% 96.0% 8.65% 





Table 3 Risk score ranges and observed and expected lung cancers by risk decile for LLPv2 and LLPv3 
 


























1 (lowest risk) 7,790 0.06 – 0.17 0 (0) 10 8,457 0.03 - 0.10 0 6 
2 7,928 0.18 – 0.27 12 (2) 18 7,541 0.11 - 0.15 12 (2) 10 
3 7,180 0.28 – 0.38 12 (2) 23 6,807 0.16 - 0.20 11 (2) 12 
4 7,521 0.39 – 0.49 20 (3) 33 8,284 0.21 - 0.28 25 (4) 20 
5 7,622 0.50 – 0.69 20 (3) 45 7,042 0.29 - 0.37 16 (3) 23 
6 7,562 0.70 – 1.00 20 (3) 64 7,887 0.38 - 0.56 24 (4) 37 
7 7,614 1.01 – 1.61 49 (8) 97 7,154 0.57 - 0.82 36 (6) 49 
8 7,555 1.62 – 2.63 72 (12) 152 7,747 0.83 - 1.39 76 (13) 84 
9 7,687 2.64 – 5.08 131 (22) 283 7,500 1.40 - 2.64 130 (22) 145 
10 (highest risk) 7,499 5.09 – 53.71 263 (44) 711 7,539 2.65 - 34.72 269 (45) 382 
All 75,958  599  1,436 75,958  599 768 
* these are not equal, since individuals were allocated to groups by an algorithm which ensure all those with the same score 







Figure 1 ROC curve for LLPv3 
 
Figure 2 Observed vs predicted log odds of cancer for LLPv2 and LLPv3 
Figure 3 Observed vs predicted log odds of cancer for LLPv3 (a) Males; (b) Females. 
 
